Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline

CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from $86 to $80. The firm highlighted that much of the pipeline remains undervalued and noted that the company could begin late-stage development for up to seven opportunities in 2027.

Earlier on January 6, Bank of America analyst Alec Stranahan reduced the firm’s price target for CRISPR Therapeutics (NASDAQ:CRSP) to $90 from $93 while maintaining a Buy rating. This sentiment was posted as the firm adjusted price targets across its US Biopharmaceuticals coverage.

BofA specifically noted that recently, various factors have aligned, such as rewards for positive data, large-cap biopharma investing in M&A & licensing, an increasing private company backlog, better capital access, and minimal drug price regulation effects. The firm suggested that biotech has returned, though the primary uncertainty remains the trend’s longevity.

CRISPR Therapeutics (NASDAQ:CRSP) is a gene editing company that develops gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.